ECSP21051833A - Combinación de dextrometorfano y bupropión para el tratamiento de depresión - Google Patents
Combinación de dextrometorfano y bupropión para el tratamiento de depresiónInfo
- Publication number
- ECSP21051833A ECSP21051833A ECSENADI202151833A ECDI202151833A ECSP21051833A EC SP21051833 A ECSP21051833 A EC SP21051833A EC SENADI202151833 A ECSENADI202151833 A EC SENADI202151833A EC DI202151833 A ECDI202151833 A EC DI202151833A EC SP21051833 A ECSP21051833 A EC SP21051833A
- Authority
- EC
- Ecuador
- Prior art keywords
- bupropion
- dextrometorphan
- depression
- treatment
- combination
- Prior art date
Links
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001058 bupropion Drugs 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 title 1
- MKXZASYAUGDDCJ-CGTJXYLNSA-N levomethorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(C)[C@@H]2CC2=CC=C(OC)C=C21 MKXZASYAUGDDCJ-CGTJXYLNSA-N 0.000 title 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 abstract 2
- 229960001985 dextromethorphan Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se divulgan las formas de dosificación, sistemas de suministro de fármacos y métodos relacionados con la liberación sostenida de dextrometorfano o efectos terapéuticos mejorados. Típicamente, bupropión o un compuesto relacionado se administra por vía oral a un ser humano a ser tratado con o que es tratado con dextrometorfano.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789451P | 2019-01-07 | 2019-01-07 | |
| US201962789431P | 2019-01-07 | 2019-01-07 | |
| US201962789446P | 2019-01-07 | 2019-01-07 | |
| US201962789488P | 2019-01-07 | 2019-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21051833A true ECSP21051833A (es) | 2021-11-18 |
Family
ID=71521902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202151833A ECSP21051833A (es) | 2019-01-07 | 2021-07-13 | Combinación de dextrometorfano y bupropión para el tratamiento de depresión |
Country Status (28)
| Country | Link |
|---|---|
| EP (2) | EP4631571A3 (es) |
| JP (1) | JP2022516361A (es) |
| KR (2) | KR20240169131A (es) |
| CN (4) | CN112437659B (es) |
| AU (3) | AU2020207261B2 (es) |
| BR (1) | BR112020025902A2 (es) |
| CA (2) | CA3223187A1 (es) |
| CL (1) | CL2021001810A1 (es) |
| CO (1) | CO2021008988A2 (es) |
| CR (1) | CR20210368A (es) |
| DK (1) | DK3908270T3 (es) |
| EC (1) | ECSP21051833A (es) |
| ES (1) | ES3051232T3 (es) |
| FI (1) | FI3908270T3 (es) |
| HR (1) | HRP20251402T1 (es) |
| IL (1) | IL284663A (es) |
| LT (1) | LT3908270T (es) |
| MX (1) | MX2021008247A (es) |
| MY (1) | MY201603A (es) |
| NZ (1) | NZ777261A (es) |
| PE (1) | PE20212249A1 (es) |
| PL (1) | PL3908270T3 (es) |
| PT (1) | PT3908270T (es) |
| RS (1) | RS67453B1 (es) |
| SG (1) | SG11202106392RA (es) |
| SI (1) | SI3908270T1 (es) |
| SM (1) | SMT202600055T1 (es) |
| WO (1) | WO2020146412A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12569479B2 (en) | 2016-05-25 | 2026-03-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| DK3908270T3 (da) * | 2019-01-07 | 2025-11-17 | Antecip Bioventures Ii Llc | Kombination af dextromethorphan og bupropion til behandling af depression hos asiatiske patienter |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| WO2022119981A1 (en) | 2020-12-01 | 2022-06-09 | Antecip Bioventures Ii Llc | Bupropion and dextromethrophan for reduction of suicide risk in depression patients |
| AU2022316152A1 (en) * | 2021-07-21 | 2024-02-01 | Antecip Bioventures Ii Llc | Treatment of depression |
| CA3229053A1 (en) * | 2021-08-09 | 2023-02-16 | Antecip Bioventures Ii Llc | Method of maintaining remission of depressive symptoms |
| CN119212709A (zh) * | 2022-05-17 | 2024-12-27 | 安泰赛普生物风投二代有限责任公司 | 抑郁的治疗 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| WO2025117954A1 (en) * | 2023-12-01 | 2025-06-05 | Axsome Therapeutics, Inc. | Compounds and combinations thereof for treating depression in patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007212586A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| CN107669649A (zh) * | 2012-10-11 | 2018-02-09 | Ix生物制药有限公司 | 固体剂型 |
| CA2899455C (en) * | 2013-01-30 | 2021-06-08 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
| US9402843B2 (en) * | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| CN110279682A (zh) * | 2013-11-05 | 2019-09-27 | 安泰赛普生物风投二代有限责任公司 | 包含安非他酮或相关化合物和右美沙芬的组合物和方法 |
| US10512643B2 (en) * | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| SG10201901242PA (en) * | 2014-09-14 | 2019-03-28 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
| HUE052609T2 (hu) * | 2014-11-21 | 2021-05-28 | Antecip Bioventures Ii Llc | Bupropion dextromorfán gyógyszer plazmaszintek modulálására |
| DK3908270T3 (da) * | 2019-01-07 | 2025-11-17 | Antecip Bioventures Ii Llc | Kombination af dextromethorphan og bupropion til behandling af depression hos asiatiske patienter |
-
2020
- 2020-01-07 DK DK20737928.0T patent/DK3908270T3/da active
- 2020-01-07 PL PL20737928.0T patent/PL3908270T3/pl unknown
- 2020-01-07 MX MX2021008247A patent/MX2021008247A/es unknown
- 2020-01-07 SM SM20260055T patent/SMT202600055T1/it unknown
- 2020-01-07 CN CN202080004041.1A patent/CN112437659B/zh active Active
- 2020-01-07 SI SI202030682T patent/SI3908270T1/sl unknown
- 2020-01-07 CA CA3223187A patent/CA3223187A1/en active Pending
- 2020-01-07 NZ NZ777261A patent/NZ777261A/en unknown
- 2020-01-07 EP EP25191016.2A patent/EP4631571A3/en active Pending
- 2020-01-07 HR HRP20251402TT patent/HRP20251402T1/hr unknown
- 2020-01-07 EP EP20737928.0A patent/EP3908270B1/en active Active
- 2020-01-07 KR KR1020247038482A patent/KR20240169131A/ko active Pending
- 2020-01-07 PT PT207379280T patent/PT3908270T/pt unknown
- 2020-01-07 CN CN202210286769.9A patent/CN114712358A/zh active Pending
- 2020-01-07 KR KR1020217023974A patent/KR20210110654A/ko not_active Ceased
- 2020-01-07 PE PE2021001138A patent/PE20212249A1/es unknown
- 2020-01-07 ES ES20737928T patent/ES3051232T3/es active Active
- 2020-01-07 CR CR20210368A patent/CR20210368A/es unknown
- 2020-01-07 AU AU2020207261A patent/AU2020207261B2/en active Active
- 2020-01-07 WO PCT/US2020/012612 patent/WO2020146412A1/en not_active Ceased
- 2020-01-07 CN CN202210286767.XA patent/CN114712357A/zh active Pending
- 2020-01-07 SG SG11202106392RA patent/SG11202106392RA/en unknown
- 2020-01-07 RS RS20251154A patent/RS67453B1/sr unknown
- 2020-01-07 CN CN202210286580.XA patent/CN114712356A/zh active Pending
- 2020-01-07 JP JP2021539451A patent/JP2022516361A/ja active Pending
- 2020-01-07 BR BR112020025902-0A patent/BR112020025902A2/pt not_active Application Discontinuation
- 2020-01-07 CA CA3126062A patent/CA3126062C/en active Active
- 2020-01-07 LT LTEPPCT/US2020/012612T patent/LT3908270T/lt unknown
- 2020-01-07 MY MYPI2021003336A patent/MY201603A/en unknown
- 2020-01-07 FI FIEP20737928.0T patent/FI3908270T3/fi active
-
2021
- 2021-07-06 IL IL284663A patent/IL284663A/en unknown
- 2021-07-07 CO CONC2021/0008988A patent/CO2021008988A2/es unknown
- 2021-07-07 CL CL2021001810A patent/CL2021001810A1/es unknown
- 2021-07-13 EC ECSENADI202151833A patent/ECSP21051833A/es unknown
-
2023
- 2023-07-06 AU AU2023204348A patent/AU2023204348B2/en active Active
-
2025
- 2025-05-23 AU AU2025203831A patent/AU2025203831A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21051833A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| ECSP22036502A (es) | Inhibidores del factor d del complemento para administraci?n oral | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| MX2023003097A (es) | Composiciones farmaceuticas que comprenden un oligonucleotido antisentido para administracion oral. | |
| MX2022008148A (es) | Inhibidores de btk. | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| AR109693A1 (es) | Formulaciones de liberación inmediata de oprozomib | |
| PE20221314A1 (es) | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro | |
| PE20210370A1 (es) | Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
| PA8624501A1 (es) | Piperazinas derivadas de úrea para el tratamiento de la endometrosis | |
| CL2024000781A1 (es) | Formas farmacéuticas multipartículas que comprenden deutetrabenazina | |
| BR112018017167A2 (pt) | titulação de cebranopadol | |
| CO2021014967A2 (es) | Composiciones farmacéuticas de combinación a dosis fijas de liberación inmediata, métodos y usos de las mismas | |
| AR120453A1 (es) | Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer | |
| MX2016006375A (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| MX2022000426A (es) | Telmisartan para el tratamiento de la hipertension en perros. | |
| CL2019002936A1 (es) | Uso de ácido 1-(aminometil) ciclohexanoacético para preparar un medicamento útil para el tratamiento y prevención de la enfermedad de alzheimer | |
| EA202190247A1 (ru) | ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |